Cargando…
Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan
The purpose of the present study is to investigate the concordance of treatment preferences between patients and physicians in prostate cancer (PCa) in Japan. An internet-based discrete choice experiment was conducted. Patients and physicians were asked to select their preferred treatment from a pai...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131454/ https://www.ncbi.nlm.nih.gov/pubmed/29774804 http://dx.doi.org/10.1177/1557988318776123 |
_version_ | 1783354107781709824 |
---|---|
author | Nakayama, Masahiko Kobayashi, Hisanori Okazaki, Masateru Imanaka, Keiichiro Yoshizawa, Kazutake Mahlich, Jörg |
author_facet | Nakayama, Masahiko Kobayashi, Hisanori Okazaki, Masateru Imanaka, Keiichiro Yoshizawa, Kazutake Mahlich, Jörg |
author_sort | Nakayama, Masahiko |
collection | PubMed |
description | The purpose of the present study is to investigate the concordance of treatment preferences between patients and physicians in prostate cancer (PCa) in Japan. An internet-based discrete choice experiment was conducted. Patients and physicians were asked to select their preferred treatment from a pair of hypothetical treatments consisting of four attributes: quality of life (QOL), treatment effectiveness, side effects, and accessibility of treatment. The data were analyzed using a conditional logistic regression model to calculate coefficients and the relative importance (RI) of each attribute. A total of 103 PCa patients and 127 physicians responded. The study looked at 37 patients considered as advanced PCa and 66 who were non-advanced PCa. All of the physicians were urologists. Advanced PCa patients ranked the attributes as follows: treatment effectiveness (RI: 32%), accessibility of treatment (RI: 26%), QOL (RI: 23%), and side effects (RI: 19%). For physicians, the RI ranking was the same as for advanced PCa patients; treatment effectiveness (RI: 29%), accessibility of treatment (RI: 27%), QOL (RI: 26%), and side effects (RI: 18%). For non-advanced PCa patients, accessibility of treatment ranked the highest RI (27%) and treatment effectiveness ranked as the lowest RI (14%). Our study suggests that the ranking of the attributes was consistent between advanced PCa patients and physicians. The most influential attribute was treatment effectiveness. Treatment preferences also vary by disease stage. |
format | Online Article Text |
id | pubmed-6131454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-61314542018-09-13 Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan Nakayama, Masahiko Kobayashi, Hisanori Okazaki, Masateru Imanaka, Keiichiro Yoshizawa, Kazutake Mahlich, Jörg Am J Mens Health Original Articles The purpose of the present study is to investigate the concordance of treatment preferences between patients and physicians in prostate cancer (PCa) in Japan. An internet-based discrete choice experiment was conducted. Patients and physicians were asked to select their preferred treatment from a pair of hypothetical treatments consisting of four attributes: quality of life (QOL), treatment effectiveness, side effects, and accessibility of treatment. The data were analyzed using a conditional logistic regression model to calculate coefficients and the relative importance (RI) of each attribute. A total of 103 PCa patients and 127 physicians responded. The study looked at 37 patients considered as advanced PCa and 66 who were non-advanced PCa. All of the physicians were urologists. Advanced PCa patients ranked the attributes as follows: treatment effectiveness (RI: 32%), accessibility of treatment (RI: 26%), QOL (RI: 23%), and side effects (RI: 19%). For physicians, the RI ranking was the same as for advanced PCa patients; treatment effectiveness (RI: 29%), accessibility of treatment (RI: 27%), QOL (RI: 26%), and side effects (RI: 18%). For non-advanced PCa patients, accessibility of treatment ranked the highest RI (27%) and treatment effectiveness ranked as the lowest RI (14%). Our study suggests that the ranking of the attributes was consistent between advanced PCa patients and physicians. The most influential attribute was treatment effectiveness. Treatment preferences also vary by disease stage. SAGE Publications 2018-05-18 2018-07 /pmc/articles/PMC6131454/ /pubmed/29774804 http://dx.doi.org/10.1177/1557988318776123 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Articles Nakayama, Masahiko Kobayashi, Hisanori Okazaki, Masateru Imanaka, Keiichiro Yoshizawa, Kazutake Mahlich, Jörg Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan |
title | Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in
Japan |
title_full | Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in
Japan |
title_fullStr | Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in
Japan |
title_full_unstemmed | Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in
Japan |
title_short | Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in
Japan |
title_sort | patient preferences and urologist judgments on prostate cancer therapy in
japan |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131454/ https://www.ncbi.nlm.nih.gov/pubmed/29774804 http://dx.doi.org/10.1177/1557988318776123 |
work_keys_str_mv | AT nakayamamasahiko patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan AT kobayashihisanori patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan AT okazakimasateru patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan AT imanakakeiichiro patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan AT yoshizawakazutake patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan AT mahlichjorg patientpreferencesandurologistjudgmentsonprostatecancertherapyinjapan |